Our short, quick and targeted approach mixes qualitative and quantitative analysis. By applying market data, history, science and quantitative methods; we synthesize metrics of pricing the RegMed universe. RMI incorporates market dynamics, answering crucial questions and generating actionable investment recommendations.
Understanding and knowing the answer as the release is issued requires a historical knowledge of sector pricing to more than “questimate” share perception and rebounds.
September 15, 2020
Q2/20 Earnings - (LPS - loss-per-share) Results
May 10, 2020
MiMedx (OTC PINK: MDXG) pays back PPP Loan
April 11, 2020
Regenerative Medicine Earnings Scorecard - Q4 & FY19
April 7, 2020
Sage Therapeutics (SAGE) Restructuring
March 29, 2020
RegMed Investors’ (RMi): the coming week ...
February 29, 2020
An introductory homily followed by a short gospel according to Henry
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at firstname.lastname@example.org.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors